top of page

Delegate Resources

These resources are for ESM Congress delegates only.

Please do not share.

Abstracts

GL03

Invited speaker

The Evolutionary History and Phylogeny of Mycobacteria

Roland Brosch, Institut Pasteur

GL04

Invited speaker

Canonical fact versus hypothesis testing to decipher transmission of non-tuberculous and tuberculous mycobacteria: a comparative review

Jean-François Guégan, UMR MIVEGEC, Montpellier, France

GL07

Invited speaker

Early host immune determinants of protection and disease progression in tuberculosis

William Branchett, Crick Institute, London

GL08

Invited speaker

Progress and challenges in tuberculosis vaccine development

Helen McShane, The University of Oxford

GL09

Invited speaker

Rethinking NTM management: new drugs, new approaches, new hope

Natalie Lorent, KU Leuven

GL10

Invited speaker

Neglected mycobacterial diseases - Continuing challenges for a hopeful future

Leen Rigouts, Institute of Tropical Medicine, Antwerp

GL11

Invited speaker

Leprosy: back to the future

Emmanuelle Cambau, APHP-GHU Nord & Université Paris Cité

GL12

Invited speaker

From Abyss to Mycobacterial Drug Discovery

Hannu Myllykallio, CNRS, Ecole polytechnique; Palaiseau, France

GMeissner

Invited speaker

Subclonal mmpR5 SNPs Co-occurring with Frameshifts Reveal Hidden Diversity of Bedaquiline Resistance Mechanisms

Jody Phelan, London School of Hygiene and Tropical Medicine

OR01

Molecular Biology and Mycobacterial Evolution

Molecular Epidemiology of Tuberculosis in Ukraine: A Nationwide Whole-Genome Sequencing Study (2020–2023)

Dmytro Butov, Department of Infectious Diseases, Children's Infectious Diseases and Phthisiology, Kharkiv National Medical University, Kharkiv, Ukraine

OR02

Molecular Biology and Mycobacterial Evolution

CRISPR and phage footprints reveal an aquatic ancestry for the tuberculosis pathogen

Arash Ghodousi, Vita-Salute San Raffaele University

OR03

Molecular Biology and Mycobacterial Evolution

Interred mechanisms of resistance and host immune evasion revealed through network-connectivity analysis of M. tuberculosis complex graph pangenome

Faramarz Valafar, San Diego State University

OR04

Molecular Biology and Mycobacterial Evolution

Genome-wide association analysis of Mycobacterium tuberculosis lineage 2 reveals key factors for its enhanced epidemic success

Nour Gharbi, EPHE, PSL University, Paris, France

OR05

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

Standardised protocol for the detection and quantification of nontuberculous mycobacteria in tap water and its application in investigating the source of clinical infections

Camille Allam, Centre National de Référence des Mycobactéries et de la Résistance aux Antituberculeux (CNR MyrMA)

OR06

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

Indoor water systems as reservoirs for clinically relevant non-tuberculous mycobacteria in Germany

Margo Diricks, Research Center Borstel

OR07

Neglected mycobacterial diseases

TB through a One Health lens: Challenges in a rural South African setting

Anita Michel, University of Pretoria

OR08

Molecular Biology and Mycobacterial Evolution

Nontuberculous Mycobacteria in Denmark: Seven Decades of Clinical Occurrence

Xenia Emilie Sinding Iversen, International Reference Laboratory of Mycobacteriology, Statens Serum Institut, 2300 Copenhagen S, Denmark

OR09

Host-Pathogen interactions in TB

Mycobacterium tuberculosis trehalose synthesis pathways as key determinant of tuberculosis disease progression

Javier Alonso del Real, University of Valencia

OR10

Host-Pathogen interactions in TB

Region-Specific Spatial Transcriptomics Reveal Distinct Immunological Functions in Human Tuberculosis Granulomas

Tobias Dallenga, Cellular Microbiology, Research Center Borstel, Germany

OR11

Host-Pathogen interactions in TB

Reprogramming of human macrophages in response to Mycobacterium tuberculosis complex (MTBC) infection

Jana Schoenfeld, Research Center Borstel Leibniz Lung Center

OR12

Host-Pathogen interactions in TB

Autologous host-pathogen pairing enhances early immune responses and bacterial control in tuberculosis ex vivo granuloma model

Charlotte Genestet, International Center for Infectious Disease Research (CIRI), Lyon, France

OR13

Clinical pathology and diagnostic advances

Use of large-scale clinical samples to progressively create a reference catalogue of mycobacterial species.

P W Fowler, University of Oxford

OR14

Clinical pathology and diagnostic advances

SIILTIBCY: A New Era in TB Diagnosis

Marcus May, Serum Life Science

OR15

Clinical pathology and diagnostic advances

Genotypic drug susceptibility testing for new tuberculosis treatment regimens: The challenge of comprehensive and reliable WHO catalogue-based sequencing data interpretation

Noud Hermans, KNCV tuberculosis foundation, The Hague, The Netherlands

OR16

Molecular Biology and Mycobacterial Evolution

Complete genomes reveal unprecedented genomic diversity of Mycobacterium tuberculosis complex from global to within-host variation

Iñaki Comas, Instituto de Biomedicina de Valencia - Spanish National Research Council

OR17

Recent advances in research on Mycobacterial pathogenesis

When Non-Pathogens Kill: Mycolicibacterium manresensis as a Model for Cryptic Virulence in Mycobacteria

Mariona Cortacans, Unitat de Tuberculosi Experimental. Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona (08916), Catalonia, Spain

OR18

Recent advances in research on Mycobacterial pathogenesis

Investigating the virulence of Mycobacterium abscessus using the Drosophila melanogaster infection model

Marta Arch, Institut d'investigació en Ciències de la Salut Germans Trias i Pujol

OR19

New generation vaccines for TB

Evaluation of immune responses elicited by respiratory mucosal vaccination strategies against TB in a goat model

Patricia Cuenca Lara, Programa de Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), IRTA, Campus de la Universitat Autònoma de Barcelona, Bellaterra, 08193, Catalonia, Spain.

OR20

Clinical pathology and diagnostic advances

Utility of targeted Nanopore sequencing for the detection of drug-resistant tuberculosis in Kyrgyzstan

Kristin Kremer, KNCV Tuberculosis Foundation, The Hague, The Netherlands

OR21

New generation vaccines for TB

Immunopeptidomics for vaccines against tuberculosis

Paulo Bettencourt, Faculty of Medicine, Universidade Católica Portuguesa, 2635-631 Rio de Mouro, Portugal

OR22

Molecular Biology and Mycobacterial Evolution

Determining the genetic drivers of pathogenicity in the genus Mycobacterium

Oren Tzfadia, Institute of Tropical Medicine, Antwerp

OR23

Therapeutic strategies for NTM

Single-cell RNA sequencing shows that circulating monocytes enriched in IFN signaling are associated with nontuberculous mycobacteria pulmonary disease in cystic fibrosis 

Nicola Lore, San Raffael Scientific Institute

OR24

Therapeutic strategies for NTM

International Consensus Framework for Managing Treatment Failure in Nontuberculous Mycobacterial Pulmonary Disease

D Moreira-Sousa, Pulmonology Department, Local Health Unit Cova da Beira, Covilhã, Portugal

OR25

Therapeutic strategies for NTM

Fidaxomicin, a potential new drug for combinatorial therapies against Mycobacterium abscessus.

Chloé Jacquet, Inserm U1070 PHAR2, Pharmacology of Antimicrobial Agents and Antibioresistance

OR26

Therapeutic strategies for NTM

Evaluation of NTM-Profiler for identification and drug resistance prediction in nontuberculous mycobacteria from whole genome sequencing data

Simone Mok, Irish Mycobacteria Reference Laboratory, St. James’s Hospital, Dublin, Ireland

OR27

Host-Pathogen interactions in TB

Modeling a genetic condition that protects against tuberculosis

Aarnoud van der Spoel, Dalhousie University

OR28

Therapeutic strategies for NTM

Preclinical murine models for studying lung infection and antimicrobial treatments of Nontuberculous mycobacteria

Fabio Saliu, San Raffaele Scientific Institute

OR29

Neglected mycobacterial diseases

Validating a SNP calling pipeline for Mycobacterium leprae

Conor Meehan, Nottingham Trent University

OR30

Neglected mycobacterial diseases

The diagnostic potential of Mycobacterium ulcerans Mycolactone and the surface protein MUL_3720

Louisa Warryn, Swiss Tropical and Public Health Institute

OR31

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

Natural drivers and Human-Induced Pressures shaping the distribution of Mycobacterium ulcerans and Buruli Ulcer

Alisa Aliaga Samanez, 1. MIVEGEC (UMR Université de Montpellier, CNRS, IRD), Montpellier, France.

OR32

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

Solving the transmission enigma of Buruli ulcer (Mycobacterium ulcerans infection)

Tim Stinear, University of Melbourne

OR33

Systems Biology Approaches to Accelerate Mycobacteriosis Drug Discovery

Implementing large-scale genomics and genomic subtractive strategies to expand the target space in Mycobacterium tuberculosis: a strategy for improving target-based drug discovery

P Gomes, Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal

OR34

Systems Biology Approaches to Accelerate Mycobacteriosis Drug Discovery

Exploring in silico drug repurposing to develop new therapeutic alternatives for tuberculosis

Liliana Rodrigues, Global Health and Tropical Medicine, GHTM, LA-REAL, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, UNL, Lisboa, 1349-008, Portugal

OR35

Clinical pathology and diagnostic advances

DprE1 inhibitors and bedaquiline combination for TB treatment: in-vitro and in-silico analyses

Andrea Muscetti, San Raffaele Scientific Institute

OR36

Systems Biology Approaches to Accelerate Mycobacteriosis Drug Discovery

Improved models for drug development against non-tuberculous mycobacteria

Salomé Gomes, Universidade do Porto

P001

Recent advances in research on Mycobacterial pathogenesis

Modeling co-Infection of Mycobacterium abscessus and Pseudomonas aeruginosa in lab and animal models

Esther Julian, Universitat Autònoma de Barcelona

P002

Recent advances in research on Mycobacterial pathogenesis

Microbiota modulation of mycobacteria-based immunotherapy in the orthotopic murine model of bladder cancer

Arnau Seguí Moll, Universitat Autònoma de Barcelona

P003

Clinical pathology and diagnostic advances

Increased sensitivity for Mycobacterium tuberculosis detection with the updated FluoroType MTBDR v2

Erik Svensson, Statens Serum Institut

P004

Clinical pathology and diagnostic advances

Diagnostic accuracy and operational assessment of microscopy and molecular tests for pulmonary tuberculosis in Panama

Dilcia Sambrano, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología de Panama, Ciudad del Saber, Panamá

P005

Clinical pathology and diagnostic advances

Role of the inhA_S94A Mutation on drug resistance and the spread of an Isoniazid-Resistant Tuberculosis strain

Anna Roig Guill, Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia, CSIC, Valencia, 46011 Spain

P006

Clinical pathology and diagnostic advances

Diagnostic capacity and Biosafety practices for Tuberculosis: Assessment of the Portuguese National Laboratory Network

Ana Rita Macedo, National Reference Laboratory for Mycobacteria, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge, Portugal

P007

Clinical pathology and diagnostic advances

Speeding up drug susceptibility testing in Mycobacterium tuberculosis using RNA biomarkers

Margo Maex, Sciensano, Brussels, Belgium

P008

Clinical pathology and diagnostic advances

Evaluating the performance of broth microdilution for the detection of rifampicin-resistant tuberculosis caused by borderline rpoB mutants

Noor Hidayatallah, Institute of Tropical Medicine Antwerp

P009

Clinical pathology and diagnostic advances

Treatment of a dog with active tuberculosis (Poland)

Ewelina Szacawa, National Veterinary Research Institute in Pulawy, Poland

P010

Clinical pathology and diagnostic advances

Tuberculosis in alpacas in Poland in 2018-2019

Ewelina Szacawa, National Veterinary Research Institute in Pulawy, Poland

P011

Clinical pathology and diagnostic advances

Culture-Free Targeted Whole Genome Enrichment of Mycobacterium tuberculosis and Next-Generation Sequencing Enables Rapid Surveillance of Drug Resistance and Genomic Tracking.

Dylan Barbera, QIAGEN Sciences

P012

Clinical pathology and diagnostic advances

Detection of first-line and second-line Drug-Resistance mediating mutations in Mycobacterium tuberculosis with FluoroLyse and GenoXtract fleXT extracted DNA from sputum Using Next-Generation Sequencing 

V Allerheiligen, Hain Lifescience GmbH - A Bruker company

P013

Clinical pathology and diagnostic advances

Impact of 'borderline' rpoB mutations on the MICs of Mycobacterium tuberculosis against new and repurposed anti-tuberculosis drugs

Praharshinie Rupasinghe, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp

P015

Clinical pathology and diagnostic advances

Overcoming barriers for non-tuberculous Mycobacteria identification: application of a culture-independent targeted sequencing approach

Ana Rita Macedo, National Reference Laboratory for Mycobacteria, Department of Infectious Diseases, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal

P016

Clinical pathology and diagnostic advances

Mycobacterium avium bacteriemia: direct identification and genotypic susceptibility characterization from positive blood culture bottles

Anna Camaggi, Laboratory of Microbiology and Virology, University Hospital “Maggiore della Carità”, Novara, Italy

P017

Clinical pathology and diagnostic advances

Isolation of Mycobacterium nebraskense in four oncolocic patients

Anna Camaggi, Laboratory of Microbiology and Virology, University Hospital “Maggiore della Carità”, Novara, Italy

P018

Clinical pathology and diagnostic advances

Widespread preexisting resistance to new and repurposed anti-tuberculosis drugs through loss-of-function

D Conkle-Gutierrez, San Diego State University

P019

Clinical pathology and diagnostic advances

Culture-free sequencing of M. tuberculosis: evaluating targeted and whole-genome approaches for genotyping and drug-resistance detection

Ilaria Iannucci, San Raffael Scientific Institute

P020

Clinical pathology and diagnostic advances

Big MAC: whole-genome sequencing uncovers novel members of the Mycobacterium avium complex unidentified at the species level by line-probe assays

Anders Norman, Statens Serum Institut

P021

Clinical pathology and diagnostic advances

Piloting Precision: Implementation of targeted next generation sequencing for antibiotic resistance testing into the diagnostic algorithm of Tuberculosis in Kyrgyzstan

Christian Utpatel, Research Center Borstel

P022

Clinical pathology and diagnostic advances

Acceptance of tongue swabs for tuberculosis screening among healthcare workers in Italy: a qualitative study

Renee CODSI, University of Washington

P023

Molecular Biology and Mycobacterial Evolution

Genetic characterisation of Mycobacterium bovis strains isolated from cattle in Northern Africa

Isabel Dickie, The Royal Veterinary College

P024

Clinical pathology and diagnostic advances

Rapidly and reproducibly building a catalogue of resistance-associated variants using 53,700 M. tuberculosis samples with genomes and DST data.

Dylan Adlard, University of Oxford

P025

Clinical pathology and diagnostic advances

Growth phase-specific DNA methylation bias in Mycobacterium tuberculosis clinical isolates

S J Modlin, San Diego State University

P026

Clinical pathology and diagnostic advances

Lung ultrasound for the detection of pulmonary tuberculosis using expert- and AI-guided interpretation: a prospective cohort study

Veronique Suttels, Lausanne University Hospital

P027

Clinical pathology and diagnostic advances

Subpopulations in clinical samples of M. tuberculosis can give rise to rifampicin resistance and shed light on how resistance was acquired

Viktoria Brunner, University of Oxford

P028

Clinical pathology and diagnostic advances

Emergence and reversion of rifampicin resistance during discontinuous treatment of tuberculosis in an HIV patient

Charlotte Genestet, International Center for Infectious Disease Research (CIRI), Lyon, France

P029

Clinical pathology and diagnostic advances

Use of large-scale clinical samples to progressively create a reference catalogue of mycobacterial species.

P W Fowler, University of Oxford

P030

Clinical pathology and diagnostic advances

Acceptability of tongue swabs for tuberculosis screening in migrant settings: A qualitative study with healthcare workers in Lombardy, Italy

Renee CODSI, University of Washington

P031

Clinical pathology and diagnostic advances

Rapid drug resistance prediction in positive Mycobacterium tuberculosis clinical samples using an extensive targeted next-generation sequencing panel

Rita Macedo, National Reference Laboratory for Mycobacteria, Infectious Diseases Department, National Institute of Health Doctor Ricardo Jorge

P032

Clinical pathology and diagnostic advances

Evaluation of new microdilution Plates (FRATMYC1 and FRATMYC2) for drug susceptibility testing to old and new antibiotics against slow growing non-tuberculous mycobacteria

Corentin Poignon, AP-HP Sorbonne University

P033

Clinical pathology and diagnostic advances

Evaluation of an Oxford Nanopore sequencing workflow for mycobacteria from primary MGIT culture

D W Crook, The University of Oxford

P034

Clinical pathology and diagnostic advances

Comparison of Illumina and Oxford Nanopore Technology sequencing of Mycobacterium tuberculosis

Matthew Colpus, Nuffield Department of Medicine, University of Oxford

P035

Clinical pathology and diagnostic advances

Stool based diagnostics for TB: who stands the benefit and how far are countries with the implementation.

Petra de haas, KNCV TB foundation

P036

Clinical pathology and diagnostic advances

A rapid DNA extraction method from clinical culture isolates for mycobacteria identification using INNO-LiPA mycobacteria v2.

Dennis Chye Sheng Gan, Duke-NUS Medical School

P037

Host-Pathogen interactions in TB

Exploring patterns of serum CRP level reduction in response to treatment initiation in Latvian patients with pulmonary tuberculosis: the impact of Mycobacterium tuberculosis genotype

Agnija Kivrane, Pharmacogenetic and Precision Medicine Laboratory, Pharmaceutical Education and Research Centre, Riga Stradins University, Konsula Street 21, LV1007 Riga, Latvia

P038

Host-Pathogen interactions in TB

Vitamin D receptor BsmI haplotype BB confers lower 25(OH)D levels during tuberculosis: A cross-sectional study

Dilcia Sambrano, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología

P039

Host-Pathogen interactions in TB

Chitosan-particle-based cystatin F RNA silencing as a therapeutic strategy to improve the control of intracellular Mycobacterium tuberculosis

Manoj Mandal, Host-Pathogen Interactions Unit, Research Institute for Medicines, Faculty of Pharmacy, University of Lisbon, Portugal

P040

Host-Pathogen interactions in TB

Redefining the role of the Signalling by Nuclear Receptors Pathway in Tuberculosis

Marta Silva, I3S- instituto de Investigação e Inovação em Saúde

P041

Host-Pathogen interactions in TB

Dueling forces: how glucocorticoids both help and hurt in tuberculosis.

Pablo Soldevilla, Unitat de Tuberculosi Experimental, Microbiology Dept. Germans Trias i Pujol Research Institute and Hospital (IGTP-HUGTIP), Badalona, 08916, Spain

P042

Host-Pathogen interactions in TB

Optimization of 3D culture conditions with five diferent tumor cell lines to monitor mycobacterial antitumor activity

Núria Sabando-Garcia, Universitat Autònoma de Barcelona

P043

Host-Pathogen interactions in TB

Exploring the role of Mincle in macrophage-mediated antitumoral responses

Noemí López Traba, Universitat Autònoma de Barcelona

P044

Host-Pathogen interactions in TB

In vitro modelling of the tuberculosis granuloma for antimicrobial and host-directed drug screening

David Pires, Center for Interdisciplinary Research in Health, Católica Medical School, Universidade Católica Portuguesa, Rio de Mouro 2635-631, Portugal

P045

Host-Pathogen interactions in TB

Phagocytosis of Mycobacterium fortuitum by caprine alveolar macrophages is associated with iNOS and proinflammatory marker expression

Miriam Blay Benach, Programa de Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), IRTA, Campus de la Universitat Autònoma de Barcelona, Bellaterra, 08193, Catalonia, Spain.

P046

Host-Pathogen interactions in TB

Mycobacteria extracellular vesicles as alternative immunotherapy for Bladder cancer

Bazezew Yenew Tessema, Vita-Salute San Raffaele University, Milan, Italy

P047

Molecular Biology and Mycobacterial Evolution

Pattern of genotypic mutations and level of MIC for results evaluation of drug susceptibility testing of M. tuberculosis

N CIOBANU, Institute of Pneumology "Chiril Draganiuc"; Chisinau, Moldova

P048

Molecular Biology and Mycobacterial Evolution

A next-generation LLM-interrogable mycobacterial knowledge base

Klaas Dewaele, Institute of Tropical Medicine Antwerp

P049

Molecular Biology and Mycobacterial Evolution

Comparative analysis of nanopore and illumina sequencing for molecular epidemiology of M. tuberculosis

Viktoria Szel, National Reference Laboratory for Mycobacteriology, Hungary

P050

Molecular Biology and Mycobacterial Evolution

Improving the Reproducibility of RNA Sequencing Methodologies in Mycobacterium tuberculosis: A Pilot Study on Isoniazid Treatment

Trisha Parbhoo, Research Center Borstel, Leibniz Lung Centre

P051

Molecular Biology and Mycobacterial Evolution

Transcriptional plasticity of bedaquiline-resistant Mycobacterium tuberculosis under drug pressure

Teresa Walz, Research Center Borstel

P052

Molecular Biology and Mycobacterial Evolution

GOMA:  an open-source bioinformatics pipeline for genomic characterization of Mycobacterium tuberculosis complex in low resource settings

Daniela Brites, Swiss Tropical and Public Health Institute

P053

Molecular Biology and Mycobacterial Evolution

Whole-genome sequencing for drug resistance detection and genotyping of clinical Mycobacterium tuberculosis isolates in two-year period

Eva Sodja, University Clinic Golnik

P054

Molecular Biology and Mycobacterial Evolution

Insights into Drug Resistance in Mycobacterium avium Pulmonary Disease: A Retrospective Cohort Study

Xenia Emilie Sinding Iversen, International Reference Laboratory of Mycobacteriology, Statens Serum Institute, 2300 Copenhagen S, Denmark.

P055

Molecular Biology and Mycobacterial Evolution

Benchmarking algorithms for species-level profiling of mycobacteria in shotgun metagenomic samples, and application to the distribution of known mycobacteria in soils

Luke Harrison, Centre Armand-Frappier Sante Biotechnologie - INRS

P056

Molecular Biology and Mycobacterial Evolution

Global Genomic Landscape of Mycobacterium avium: Diversity, Transmission Dynamics, and Drug Resistance Mechanisms

Sofia Matos, Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal

P057

Molecular Biology and Mycobacterial Evolution

In-depth analysis of predominant Mycobacterium tuberculosis L2.2.M3 strain from Panama, using TB-Annotator

Dilcia Sambrano, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología de Panamá

P058

Molecular Biology and Mycobacterial Evolution

When Bugs Spill Secrets: Leveraging Bacterial Genomes and Machine Learning to Identify Drivers of Recent Tuberculosis Transmission in Accra, Ghana

Marie Nancy Seraphin, University of Florida

P059

Molecular Biology and Mycobacterial Evolution

Comparison of DNA-extraction for Illumina and Oxford Nanopore Sequencing in Mycobacterial Isolates

Erik Michael Rasmussen, Statens Serum Institut, Copenhagen, Denmark

P060

Molecular Biology and Mycobacterial Evolution

The function and transcriptional regulation of M. tuberculosis efflux pumps

Robin Hanson, Royal Veterinary College, University of London

P061

Molecular Biology and Mycobacterial Evolution

RAVEN and iMAGE: An integrated approach to analyse and visualise whole genome data for Mycobacterium bovis genomic surveillance and epidemiology

Purnika Ranasinghe, Agri-Food and Biosciences Institute

P062

Molecular Biology and Mycobacterial Evolution

Comparing passed slave migration history to Mycobacterium tuberculosis  genomic population structure to reconstruct the origins of L1 tuberculosis infections in Brazil

Christophe Sola, Université Paris-Saclay

P063

Molecular Biology and Mycobacterial Evolution

Secondary antibiotic resistance in rifampicin-resistant tuberculosis in a high-burden setting

Ori Solomon, McGill University

P064

Molecular Biology and Mycobacterial Evolution

Understanding tuberculosis transmission in Latvia: insights from molecular epidemiology

Renate Ranka, Latvian Biomedical Research and Study Centre

P065

Molecular Biology and Mycobacterial Evolution

Unexpected diversity in long-term infections by non-tuberculous mycobacteria revealed by longitudinal genomic analysis

Laura Pérez, Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, España

P066

Molecular Biology and Mycobacterial Evolution

Using the mutant selection window and mathematical modelling to predict resistance selection over long-term Mycobacterium tuberculosis treatment in vitro

Lindsay Sonnenkalb, Research Center Borstel Leibniz Lung Center

P067

Molecular Biology and Mycobacterial Evolution

Investigating antibiotic-induced persistence in Mycobacterium abscessus

Lisa Geerts, University of Antwerp

P069

Molecular Biology and Mycobacterial Evolution

An alternative for high-throughput Illumina-based sequencing: Individualized nanopore analysis of new incident cases coupled to targeted sequencing

S M Saleeb, Department of Clinical Microbiology and Infectious Diseases, Gregorio Marañón General University Hospital, Madrid, Spain

P070

Molecular Biology and Mycobacterial Evolution

An extended genomic analysis reveals unexpected transmissions involving the pediatric population in Madrid with tuberculosis

Marta López Llaría, Servicio de Microbiología clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, 28009, España

P071

Molecular Biology and Mycobacterial Evolution

Lineage-dependent rifampicin tolerance in Mycobacterium tuberculosis complex strains

Annemarie Hintz-Rüter, Research Center Borstel

P072

Molecular Biology and Mycobacterial Evolution

Genomic diversity of Mycobacterium abscessus isolates in Portugal

Miguel Pinto, Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal

P073

Molecular Biology and Mycobacterial Evolution

Genomic insights into Mycobacterium avium complex isolates from Portugal reveal extensive genetic diversity

Miguel Pinto, Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal

P074

Molecular Biology and Mycobacterial Evolution

Population structure of Mycobacterium tuberculosis Lineage 2 in Kazakhstan based on whole-genome sequencing

Sabina Atavliyeva, National Center for Biotechnology, Astana, Kazakhstan

P075

Molecular Biology and Mycobacterial Evolution

Do we use the right breakpoints for delamanid susceptibility testing ?

Noémie Lequerré, UPMC - Paris 6

P076

Molecular Biology and Mycobacterial Evolution

Emergence of bedaquiline resistance in samples rifampicin resistant Tuberculosis in Mozambique

Leonardo de Araujo, Research Center Borstel, Germany

P077

Molecular Biology and Mycobacterial Evolution

Relaunching crypticproject.org: making the MTBC genetic and pDST datasets collated by the CRyPTIC project more available to the wider community

Philip Fowler, University of Oxford

P078

Molecular Biology and Mycobacterial Evolution

Uncovering hidden complexity in TB infections: A novel WGS-based method for detecting mixed MTBC infections

Viola Dreyer, Research Center Borstel - Leibniz Lung Center

P079

Molecular Biology and Mycobacterial Evolution

Transcriptomic insight into metabolic adaptations and efflux-based mechanisms underlying bedaquiline resistance

Jihad Snobre, Institute of Tropical Medicine Antwerp

P080

Molecular Biology and Mycobacterial Evolution

Different paths to progress towards a faster and more precise genomic epidemiology in tuberculosis

S M Saleeb, Department of Clinical Microbiology and Infectious Diseases, Gregorio Marañón General University Hospital, Madrid, Spain

P081

Molecular Biology and Mycobacterial Evolution

Characterization of the putative cobalt ECF importer CbiMNQO and its cobalt/nickel dependent regulation by the ArsR/SmtB-like regulator CbiR in Mycobacterium smegmatis

Elke Goethe, University of Veterinary Medicine Hannover

P082

Molecular Biology and Mycobacterial Evolution

Improving the benchmark of variant calling of M. tuberculosis using more complex in silico genomes

Adrien Le Meur, University Paris - Saclay

P083

Molecular Biology and Mycobacterial Evolution

The nature and consequence of epistasis between drug resistance mutations in Mycobacterium tuberculosis

Sonia Borrell, Swiss Tropical and Public Health Institute

P084

Molecular Biology and Mycobacterial Evolution

Genomic description of routinely laboratory-diagnosed XDR-TB strains from 2010 to 2019 in the Western Cape Province, South Africa

Elizabeth Streicher, Stellenbosch Unversity

P085

Molecular Biology and Mycobacterial Evolution

Deciphering NucS interactions to explore anti-evolution strategies against Mycobacterium tuberculosis

Rima Zein Eddine, Laboratoire d'Optique et Biosciences (LOB), Ecole Polytechnique, Inserm U1182, CNRS UMR7645, Institut Polytechnique de Paris, 91120 Palaiseau, France.

P087

Molecular Biology and Mycobacterial Evolution

Strategies to detect emerging SNPs in clustered Mycobacterium tuberculosis isolates for precision epidemiology.

Richard Anthony, National Institute for Public Health and the Environment

P088

Molecular Biology and Mycobacterial Evolution

Evolutionary dynamics of MDR-TB and the escalation of drug resistance and clinical impact: a case study from Portugal

P Gomes, Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal

P089

Molecular Biology and Mycobacterial Evolution

Whole-genome sequencing-based surveillance system for Mycobacterium tuberculosis in Portugal

Miguel Pinto, Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal

P091

Molecular Biology and Mycobacterial Evolution

Endemic transmission of a Mycobacterium tuberculosis L2.2.M3 sublineage of the L2 lineage within Colon, Panama: a prospective study

Dilcia Sambrano, Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia Panama City Panama

P092

Molecular Biology and Mycobacterial Evolution

Genomic analysis of a novel nontuberculous mycobacterial isolate causing persistent, disseminated infection after cardiac transplantation

Jason Stout, Duke University School of Medicine

P094

Molecular Biology and Mycobacterial Evolution

Phylogenetics and ESX-1 characterisation of a new human pathotype in the Mycobacterium conceptionense / Mycobacterium senegalense clade

Arnold Piek, University Medical Center Groningen

P095

Neglected mycobacterial diseases

Twenty-three years surveillance of antimicrobial resistance in leprosy

Emmanuelle Cambau, Centre national de reference des mycobactéries et résistance aux antituberculeux (CNR-MyRMA)

P096

Neglected mycobacterial diseases

The drinking water-gut microbiome axis in NTM disease

Inês Cravo Roxo, Molecular Microbiology & Microbiome Group, CNC - Center for Neurosciences and Cell Biology and CIBB - Centre for Innovative Biomedicine and Biotechnology, University of Coimbra

P097

Neglected mycobacterial diseases

Mycobacterium appelbergii sp. nov., a novel species isolated from a drinking water fountain in a rural community

Susana Alarico, CNC-UC - Center for Neuroscience and Cell Biology and CIBB - Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Portugal

P098

Neglected mycobacterial diseases

Analyzing the mycolic acids (MAs)  and lipids from the cell wall of Mycobacterium bovis strains isolated from Zacatecas and nearby regions.

Gloria Guillermina Guerrero Manriquez, Unidad Academica de Ciencias Biológicas. Universidad Autónoma de Zacatecas

P099

New generation vaccines for TB

Computational identification of broadly protective Mycobacterium tuberculosis vaccine candidate

SALEM SALMAN ALMUJRI, College of Pharmacy, King Khalid University

P100

New generation vaccines for TB

Identification of Mycobacterium avium Peptides Presented by Major Histocompatibility Complex Through Immunopeptidomics

Paulo Bettencourt, Faculty of Medicine, Universidade Católica Portuguesa, 2635-631 Rio de Mouro, Portugal

P101

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

Detected cases of Mycobacterium tuberculosis infection in domestic and companion animals – indicators of epidemiological trends and health risks

Silvio Špicic, National Reference Laboratory for Animal Tuberculosis, Department for Bacteriology and Parasitology, Croatian Veterinary Institute, Zagreb, Croatia

P102

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

GenEpi-BioTrain: Interdisciplinary training in genomic epidemiology and public health bioinformatics: 5th edition (tuberculosis focus)

Ivan Barilar, Research Center Borstel Leibniz Lung Center

P103

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

The impact of environmental factors on tuberculosis in Albania, 2023–2024

Donika Mema, Institute of Public Health , Tirana, Albania

P104

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

Linking long-term and short-term Mycobacterium tuberculosis transmission dynamics inferred form 15 years study in Orizaba, Mexico

Paula Sinisterra Sebastián, Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia, CSIC, Valencia, 46011 Spain

P105

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

Tuberculosis Alert: a board game designed to promote tuberculosis awareness and fight stigma

Pablo Soldevilla, Unitat de Tuberculosi Experimental, Microbiology Dept. Germans Trias i Pujol Research Institute and Hospital (IGTP-HUGTIP), Badalona, 08916, Spain

P106

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

Genomic Analysis of Mycobacterium chelonae isolates associated with heater-cooler units: a potential risk of infection during cardiac surgery

Simone Mok, Irish Mycobacteria Reference Laboratory, St. James’s Hospital, Dublin, Ireland

P107

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

Applications and challenges of prospective whole genome sequencing for tuberculosis public health investigations: a systematic review.

Daisy Wang, Australian National University National Center for Epidemiology and Population Health

P108

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

Recent updates to the SITVIT databases: ongoing development of the SITVITEXTEND and SITVITGeno projects

David Couvin, Institut Pasteur

P109

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

The impact, implementation, and ethics of whole genome sequencing for tuberculosis public health: staff perspectives from an outbreak in Victoria, Australia

Daisy Wang, National Center for Epidemiology and Population Health, Australian National University

P110

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

‘I was in a place where I was going to be healed. Let others think what they want’: A qualitative study on the experience of having tuberculosis in a sample of the Portuguese population

P Barbosa, EPIUnit ITR, Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal

P111

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

A multinational Delphi consensus on TB screening of migrants in Europe

A Aguiar, EPIUnit ITR, Instituto de Saúde Pública da Universidade do Porto, Universidade do Porto, Rua das Taipas, n° 135, 4050-600 Porto, Portugal

P112

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

Determining Epidemiological Cut-Off Values for BTZ-043 and Ganfeborole Using the EUCAST Reference Method

Arash Ghodousi, University Vita-Salute San Raffaele

P113

One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

Genomic Surveillance Uncovers Ongoing Tuberculosis Transmission in Catalonia (2022–2024).

Pere-Joan Cardona, Servei de Microbiologia, Laboratori Clínic Metropolitana Nord. Institut de Recerca i Hospital Germans Trias i Pujol (IGTP) – Badalona, Barcelona

P114

Systems Biology Approaches to Accelerate Mycobacteriosis Drug Discovery

Exploring LL-37-Based Synthetic Peptides to combat Multidrug-Resistant Tuberculosis: A step toward innovative therapies.

Paola Santos, Grupo Relaciones Microbianas y Epidemiológicas Aplicadas al Laboratorio Clínico y Molecular (REMA), Facultad de Ciencias de la Salud, Universidad Colegio Mayor de Cundinamarca, Bogotá, 110311, Colombia.

P115

Systems Biology Approaches to Accelerate Mycobacteriosis Drug Discovery

Validation of a cost-effective Drosophila melanogaster platform to identify novel treatments against tuberculosis

Maria Vidal Ramos, Unitat de Tuberculosi Experimental, Microbiology Dept. Germans Trias i Pujol Research Institute and Hospital (IGTP-HUGTIP), Badalona, 08916, Spain

P116

Systems Biology Approaches to Accelerate Mycobacteriosis Drug Discovery

Building a Large Dataset of Genome Mutations Associated with Antibiotic Resistance in Mycobacterium tuberculosis.

C Sola, INSERM, Universite Paris-Saclay

P117

Therapeutic strategies for NTM

In vitro activity of MRX-6038, a novel Leucyl-tRNA Synthetase inhibitor, against Mycobacterium abscessus

Michael Cynamon, Veteran’s Health Research Institute, Syracuse, NY

P118

Therapeutic strategies for NTM

Microbial Antagonism Against Nontuberculous Mycobacteria

Ana Maranha, CNC - Centre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, 3004-504 Coimbra, Portugal

ESM Logo_White.png

Registered address:
c/o TREASURER
Matthias Merker
Parkallee 1
23845 Borstel
Germany

  • Facebook
  • LinkedIn
  • YouTube

© 2021 The European Society of Mycobacteriology

bottom of page